Volume 12, Issue 2, March 2021

Index

REVIEW HEMATOLOGY

Tyrosine kinase inhibitor discontinuation in patients with chronic myelogenous leukaemia: A retrospective study and review of the literature

P. Beuselinck, J. Van Ham, N. Boeckx, T. Devos, P. Vandenberghe, G. Verhoef


Stem cell-derived natural killer cell immunotherapy

P.K.J.D. de Jonge, P.M.M. van Hauten, N.P.M. Schaap, H. Dolstra


PRACTICE GUIDELINES

Belgian guidelines for diagnosis and treatment of chronic myelomonocytic leukaemia

M. Beckers, S. Sid, A. De Becker, B. Heyrman, N. Granacher, D. Mazure, S. Meers, M-C. Vekemans, On behalf of the other members of MDS and MPN committee


PHARMACOTHERAPY

CAR-T cells: New developments and implications in lymphoma

G. Crochet, E. Collinge, H. Vellemans, A. Bosly, M. André


HEMATOCASE

Managing complement deficiencies: Not as complex as it seems

S. Kluijfhout, P. Stordeur, M. van den Akker, S. Ryckx, J. van der Werff ten Bosch


REIMBURSEMENT NEWS

New haematology reimbursements in Belgium

P. Specenier


X